Cite
HARVARD Citation
Katodritou, E. et al. (n.d.). Treatment with bortezomib‐based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. American journal of hematology. 89 (2), pp. 145-150. [Online].